FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322775128> ?p ?o ?g. }

• W4322775128 endingPage "41" @default.
• W4322775128 startingPage "P4" @default.
• W4322775128 abstract "Abstract OBJECTIVE: To evaluate the prevalence of sensitivity changes in patients during the cycle of chemotherapy with taxanes and the impacts on quality of life. DESIGN: A prospective, observational, Approved study was conducted at the Oncomastology outpatient clinic of Hospital São Paulo- Unifesp, in the period from November 2018 to February 2022, where 102 women with breast cancer were selected and 79 patients who underwent chemotherapy with paclitaxel were included. METHODS: Collection of demographic and clinical information. Used stesiometer that assessed sensitivity in dermatos and myotomes in the following body regions: arms, hands, legs and feet. FACT/GOG-Ntx Questionnaire analyzed the quality of life and chemotherapy-induced peripheral neuropathy of the patients before starting chemotherapy. All participants were informed and signed an informed consent form. RESULTS: The mean age was 49 years, mean BMI was 27.95Kg/m2, NICC (Invasive Carcinoma not special) represented 89.9% of the sample, 88.6% had Neoadjuvant Chemotherapy, regarding the size of the tumor 45.6% presented from 2 to 5 cm, of the pre existing diseases Diabetes mellitus 15.2% and Systemic Arterial Hypertension 30.4%. The initial moment in relation to sensitivity alterations, of the arm regions presented (right C6 (HC 1.05-1.23) left C6 (HC 1.05- 1.23), and legs (right L5 (HC 1.14 -1.55) left L5 (HC1.22 - 1.52) and right S1 (HC 1.21-1.47) left S1 (HC 1.21-1.48). The conversion of the Estesiometer colors into numbers followed as follows, Green (1.0): normal sensitivity, Blue (2.0): decreased sensitivity. The FACT/Taxane (TOI) quality of life Questionnaire (30 items) its scores 0-120,(average 91.44 points) demonstrates in its response impairment in more than 80 % in the quality of life in the domains. Physical Well-Being-PWB (0-28 points) (mean 20.28/HC 18.88-21.66), Functional Well-Being-FWB (0-28 points) (mean16.00/HC14.22-17.22) and in the specific questions about chemotherapy-induced peripheral neuropathy (CPIN), TaxS (0-64 points) (mean 55.16/HC 52.74-57.26) reduced scores. CONCLUSION: It is concluded that mean age, overweight, tumors between 02 and 05 cm were the most prevalent among patients diagnosed with breast cancer. At the beginning of chemotherapy containing paclitaxel, sensitivity changes were not present characterizing arthralgia, myalgia and the hand-foot syndrome (CPIN). The quality of life evaluated by FACIT/Taxane, showed a reduction of 80% in the scores of the domains Physical Well-Being-PWB, Functional Well-Being-FWB and general quality of life, that is, the quality of life of patients from the time of diagnosis is already very compromised. Key words: Breast neoplasm, adjuvant drug treatment, chemotherapy, quality of life. Number of Opinion: 2.351.174 DATA OF THE OPINION, CEP Number: 0934/2017 of the ethics in research committee. Registered in Clinical Trials on 12/12/2017, protocol number -NCT 03373032. Table 1: Results of the sensitivity of dermatos and myths (monofilaments) undergoing chemotherapy cycles with paclitaxel (eyes closed) Legend: Analysis of quantitative frequencies, Mean, Standard Deviation and Confidence Interval, Percentage (%) and Absolute number. Citation Format: Roberta P. Costa Luz, Carmen S. Alliz, Samantha K. Lopes de Almeida Rizzi, Cinira Haddad, Christiano Bittencourt Machado, Afonso Nazário, Gil Facina. Prospective observational study of breast cancer patients during the cycle of chemotherapy with taxanes: evaluation of the incidence and prevalence of peripheral neuropathy [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-03-41." @default.
• W4322775128 created "2023-03-03" @default.
• W4322775128 creator A5011813599 @default.
• W4322775128 creator A5014149724 @default.
• W4322775128 creator A5034308371 @default.
• W4322775128 creator A5042697240 @default.
• W4322775128 creator A5045635792 @default.
• W4322775128 creator A5048604183 @default.
• W4322775128 creator A5051231515 @default.
• W4322775128 date "2023-03-01" @default.
• W4322775128 modified "2023-10-16" @default.
• W4322775128 title "Abstract P4-03-41: Prospective observational study of breast cancer patients during the cycle of chemotherapy with taxanes: evaluation of the incidence and prevalence of peripheral neuropathy" @default.
• W4322775128 doi "https://doi.org/10.1158/1538-7445.sabcs22-p4-03-41" @default.
• W4322775128 hasPublicationYear "2023" @default.
• W4322775128 type Work @default.
• W4322775128 citedByCount "0" @default.
• W4322775128 crossrefType "journal-article" @default.
• W4322775128 hasAuthorship W4322775128A5011813599 @default.
• W4322775128 hasAuthorship W4322775128A5014149724 @default.
• W4322775128 hasAuthorship W4322775128A5034308371 @default.
• W4322775128 hasAuthorship W4322775128A5042697240 @default.
• W4322775128 hasAuthorship W4322775128A5045635792 @default.
• W4322775128 hasAuthorship W4322775128A5048604183 @default.
• W4322775128 hasAuthorship W4322775128A5051231515 @default.
• W4322775128 hasConcept C120665830 @default.
• W4322775128 hasConcept C121332964 @default.
• W4322775128 hasConcept C121608353 @default.
• W4322775128 hasConcept C126322002 @default.
• W4322775128 hasConcept C134018914 @default.
• W4322775128 hasConcept C141071460 @default.
• W4322775128 hasConcept C143998085 @default.
• W4322775128 hasConcept C159110408 @default.
• W4322775128 hasConcept C188816634 @default.
• W4322775128 hasConcept C23131810 @default.
• W4322775128 hasConcept C2776694085 @default.
• W4322775128 hasConcept C2779901536 @default.
• W4322775128 hasConcept C2779951463 @default.
• W4322775128 hasConcept C3020110884 @default.
• W4322775128 hasConcept C530470458 @default.
• W4322775128 hasConcept C555293320 @default.
• W4322775128 hasConcept C61511704 @default.
• W4322775128 hasConcept C71924100 @default.
• W4322775128 hasConceptScore W4322775128C120665830 @default.
• W4322775128 hasConceptScore W4322775128C121332964 @default.
• W4322775128 hasConceptScore W4322775128C121608353 @default.
• W4322775128 hasConceptScore W4322775128C126322002 @default.
• W4322775128 hasConceptScore W4322775128C134018914 @default.
• W4322775128 hasConceptScore W4322775128C141071460 @default.
• W4322775128 hasConceptScore W4322775128C143998085 @default.
• W4322775128 hasConceptScore W4322775128C159110408 @default.
• W4322775128 hasConceptScore W4322775128C188816634 @default.
• W4322775128 hasConceptScore W4322775128C23131810 @default.
• W4322775128 hasConceptScore W4322775128C2776694085 @default.
• W4322775128 hasConceptScore W4322775128C2779901536 @default.
• W4322775128 hasConceptScore W4322775128C2779951463 @default.
• W4322775128 hasConceptScore W4322775128C3020110884 @default.
• W4322775128 hasConceptScore W4322775128C530470458 @default.
• W4322775128 hasConceptScore W4322775128C555293320 @default.
• W4322775128 hasConceptScore W4322775128C61511704 @default.
• W4322775128 hasConceptScore W4322775128C71924100 @default.
• W4322775128 hasIssue "5_Supplement" @default.
• W4322775128 hasLocation W43227751281 @default.
• W4322775128 hasOpenAccess W4322775128 @default.
• W4322775128 hasPrimaryLocation W43227751281 @default.
• W4322775128 hasRelatedWork W2348231456 @default.
• W4322775128 hasRelatedWork W2354050160 @default.
• W4322775128 hasRelatedWork W2367105124 @default.
• W4322775128 hasRelatedWork W2369039771 @default.
• W4322775128 hasRelatedWork W2379009234 @default.
• W4322775128 hasRelatedWork W2379151083 @default.
• W4322775128 hasRelatedWork W2388730008 @default.
• W4322775128 hasRelatedWork W2791179561 @default.
• W4322775128 hasRelatedWork W3029286770 @default.
• W4322775128 hasRelatedWork W4321445535 @default.
• W4322775128 hasVolume "83" @default.
• W4322775128 isParatext "false" @default.
• W4322775128 isRetracted "false" @default.
• W4322775128 workType "article" @default.